<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app42.us.archive.org';v.server_ms=461;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-9855?contentType=xml', '20160930215632')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20160930215632/https://www.guideline.gov/summaries/downloadcontent/ngc-9855?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20160930215632/https://www.guideline.gov/summaries/downloadcontent/ngc-9855?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-9855?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20160930215632" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap">Aug</td>
		  <td class="c" id="displayMonthEl" title="You are here: 21:56:32 Sep 30, 2016">SEP</td>
		  <td class="f" nowrap="nowrap">Oct</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_prv_off.png" alt="Previous capture" width="14" height="16" border="0" /></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 21:56:32 Sep 30, 2016">30</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap">2015</td>
		  <td class="c" id="displayYearEl" title="You are here: 21:56:32 Sep 30, 2016">2016</td>
		  <td class="f" nowrap="nowrap">2017</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20160930215632*/https://www.guideline.gov/summaries/downloadcontent/ngc-9855?contentType=xml" title="See a list of every capture for this URL">1 capture</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-9855?contentType=xml","2016-09-30",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Winquist E, Cripps C, Agbassi C, Messersmith H, Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer. Toronto (ON): Cancer Care Ontario (CCO); 2011 Sep 30. Various p.&amp;nbsp;(Evidence-based series; no. 5-12).&amp;nbsp; [63 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Cripps C, Winquist E, Stys-Norman D, Devries M, Gilbert R, Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer: guideline recommendations. Toronto (ON): Cancer Care Ontario (CCO); 2009 May 15. 32 p.&amp;nbsp;(Evidence bases series; no. 5-12).</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=44115&quot; title=&quot;CCO Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (Stage III-IVB)</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Platinum-based chemoradiotherapy (CRT) is a recognized standard of care for the primary treatment of most patients with locally advanced HNSCC. 5-fluorouracil (5-FU) plus platin or monoplatin therapy appear most effective. In patients over age 70, the addition of platinum-based chemotherapy does not appear to provide an overall survival (OS) advantage compared to radiotherapy (RT) alone. </li>
    <li>The addition of cetuximab to intensified RT (concomitant boost or hyperfractionated schedule) may provide an alternative option to CRT. In one randomized controlled trial (RCT), this option demonstrated similar improvements in OS, progression-free survival (PFS), and time to local recurrence compared to RT alone. </li>
    <li>The role of anti-epidermal growth factor receptor (anti-EGFR) therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes. </li>
</ul>
<p><strong>Untreated Recurrent and/or Metastatic HNSCC</strong></p>
<p>Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent and/or metastatic HNSCC, and is recommended to improve OS, PFS, and response rate in suitable patients.</p>
<p><strong>Previously Treated or Unsuitable for Platinum-based Chemotherapy</strong></p>
<p>Zalutumumab appears to be of benefit in patients with recurrent and/or metastatic HNSCC who are unsuitable for cisplatin-based chemotherapy or who have had disease progression despite treatment with cisplatin-based chemotherapy.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Locally advanced (nonmetastatic [stage III or IV]) or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Assessment of Therapeutic Effectiveness"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Otolaryngology"/>
      <fieldvalue value="Pharmacology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To evaluate the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in head and neck squamous cell carcinoma (HNSCC)</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Adult patients with locally advanced (nonmetastatic [stage III or IV]) or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Platinum-based chemoradiotherapy (CRT) (5-fluorouracil [5-FU] plus platin or monoplatin therapy) </li>
    <li>Anti-epidermal growth factor receptor (anti-EGFR) therapy:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Cetuximab </li>
        <li>Gefitinib </li>
        <li>Lapatinib </li>
        <li>Zalutumumab </li>
        <li>Erlotinib </li>
        <li>Panitumumab </li>
    </ul>
    </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Overall survival (OS) </li>
    <li>Progression-free survival (PFS) </li>
    <li>Quality of life (QoL) </li>
    <li>Tumour response rate and duration </li>
    <li>Toxicity associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
      <fieldvalue value="Searches of Unpublished Data"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Literature Search Strategy</strong></p>
<p>In order to update the evidence identified in Section 2B in the original guideline document, the MEDLINE (2009 February through 2011 February week 1), EMBASE (2009 to 2011 week 6), and Cochrane Library databases (February 2011) were systematically searched for relevant articles, using the search strategy described in Appendix 1 in the original guideline document. In addition, the American Society of Clinical Oncology (ASCO) 2009 and 2010 online conference proceedings were searched for reports of new or ongoing trials. The reference lists from the relevant review articles were also searched for additional trials.</p>
<p><strong>Inclusion Criteria</strong></p>
<p>Articles were selected for inclusion in this systematic review of the evidence if they met the following criteria:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>They were abstracts or full reports of randomized phase II or III trials of epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies, either alone or in combination with radiotherapy (RT) or chemotherapy, versus a control therapy (including RT, chemotherapy, chemoradiotherapy, or best supportive care) in treatment of advanced head and neck squamous cell carcinoma (HNSCC) </li>
    <li>They reported at least one of the following outcomes: quality of life, toxicity, compliance, survival, time-to-progression, response duration, or response rate; or </li>
    <li>They were published reports of systematic reviews or evidence-based guidelines that addressed the guideline question </li>
</ul>
<p><strong>Exclusion Criteria</strong></p>
<p>Articles published in languages other than English were excluded because of limited translation resources.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The literature search update conducted in February 2011 yielded one meta-analysis and three new reports of the randomized controlled trials (RCTs) already included in the original document being retained for this update. Also, two out of 33 abstracts from the American Society of Clinical Oncology (ASCO) annual meeting proceedings contributed to the evidence base.</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Committee)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Review of Published Meta-Analyses"/>
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Synthesizing the Evidence</strong></p>
<p>Based on an a priori assumption of between-study heterogeneity, a meta-analysis was not planned but will be done, if considered appropriate.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Methods</strong></p>
<p>The Evidence-Based Series (EBS) guidelines developed by the Cancer Care Ontario Program in Evidence-based Care (CCO PEBC) use the methods of the Practice Guidelines Development Cycle. For this project, the core methodology used to develop the evidentiary base was the systematic review. Evidence was selected and reviewed by two members of the PEBC Head and Neck Cancer Disease Site Group (DSG) and two methodologists.</p>
<p><strong>Development and Internal Review</strong></p>
<p>An updated Evidence-Based Series (EBS) report was initiated by the Head and Neck Cancer DSG of the CCO PEBC in 2011 and completed in 2011. The series is a convenient and up-to-date source of the best available evidence on epidermal growth factor receptor (EGFR) targeted therapy in head and neck cancer (stage III and IV). It was developed through systematic review, evidence synthesis, and input from practitioners in Ontario. The views and preferences of the target population were not sought for. The original systematic review has been retained in Section 2B of the new series, while new evidence from February 2009 to February 2011 is presented in Section 2A in the original guideline document. The updated Guideline Recommendations are presented in Section 1 in the original guideline document.</p>
<p><strong>Disease Site Group Consensus Process</strong></p>
<p>The members of the Head and Neck Cancer DSG reviewed the new evidence contained in Section 2A in the original guideline document via email.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Report Approval Panel (RAP)</strong></p>
<p>Prior to the submission of this Evidence-Based Series (EBS) draft report for external review, the report was reviewed and approved by the Program in Evidence-Based Care (PEBC) RAP, which consists of three members: the PEBC director, the Head and Neck Disease Site Group (DSG) chair and an oncologist with expertise in methodological issues.</p>
<p><strong>External Review by Ontario Clinicians</strong></p>
<p>Following the approval of this EBS by the Head and Neck Cancer DSG members and PEBC RAP, the recommendations (see Section 1) and the evidentiary base (see Sections 2A and 2B) in the original guideline document were circulated to external reviewers in Ontario for their feedback.</p>
<p><em>Methods</em></p>
<p>The external review was conducted in two ways; by targeted peer review (TPR) and by professional consultation.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Targeted Peer Review</span></p>
<p>Seven targeted peer reviewers, from Ontario, Alberta, and Vancouver, considered to be clinical experts on the topic, were nominated by the authors. Three of the seven nominees accepted the invitation to be part of the TPR to review this EBS. On July 15th, 2011, the draft report and a five-scale questionnaire were sent to them via email. The questionnaire consists of nine items evaluating the method, results, and interpretative summary used to inform the draft recommendations. Comments from the reviewers are compiled below.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Professional Consultation</span></p>
<p>Feedback was obtained through a brief online survey of health care professionals who are the intended users of the guideline. Medical and radiation oncologists and surgeons working in the field of head and neck cancer in Ontario were identified from the PEBC database and were contacted by email to inform them of the guideline and to solicit their feedback. Participants could participate using a Web survey tool or by hardcopy through regular mail or fax. They were provided with access to the questionnaire, the guideline recommendations (Section 1 in the original guideline document), and a link to the evidentiary base (Section 2 in the original guideline document). Participants were asked to rate the overall quality of the guideline (Section 1 in the original guideline document) and whether they would use and/or recommend it. Written comments were invited.</p>
<p><strong>Conclusion</strong></p>
<p>This EBS report reflects the integration of feedback obtained through the external review process with final approval given by the Head and Neck Cancer DSG and the Report Approval Panel of the PEBC. Updates of the report will be conducted as new evidence informing the question of interest emerges.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations are supported by randomized controlled trials, one meta-analysis and abstracts from the American Society of Clinical Oncology (ASCO) annual meeting proceedings.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>The addition of cetuximab to radiotherapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) increased overall survival (OS) (median 49.0 months vs. 29.3 months; hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.57-0.97, p=0.03) and progression-free survival (PFS) (median 17.1 months vs. 12.4 months; HR 0.70, 95% CI 0.54-0.90, p=0.006) as compared with RT alone. Locoregional control (median 24.4 months vs. 14.9 months; HR 0.68, 95% CI 0.52-0.89, p=0.005) and objective response rate (74% vs. 64%; odds ratio [OR] for response 0.57, 95% CI 0.36-0.90, p=0.02) were also significantly improved. </li>
    <li>In one reported study, the addition of cetuximab to chemotherapy (cisplatin or carboplatin plus 5-fluorouracil) improved OS (10.1 months vs. 7.4 months, p=0.04), PFS (5.6 months vs. 3.3 months, p&amp;lt;0.001) and response rate (36% vs. 20%, p&amp;lt;0.001) compared to chemotherapy alone in patients with recurrent/metastatic HNSCC. </li>
    <li>In a small randomized trial, the addition of cetuximab to cisplatin improved the objective response rate (26% vs. 10%, p=0.03) but did not improve OS (9.2 months vs. 8.0 months, p=0.21) or PFS (4.2 months vs. 2.7 months, p=0.09), although the trial was inadequately powered to assess these outcomes. </li>
    <li>In one trial, PFS was shown to be significantly better in patient treated with zalutumumab than those on best supportive care (BSC) (HR, 0.63; 95% CI, 0.47 to 0.84; p=0.001). The improvement seen in OS (6.7 months versus 5.2 months) was not statistically significant (p=0.062). Zalutumumab was given in escalating doses until the patient developed a rash. </li>
</ul>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Cetuximab did not appear to increase common adverse effects that can occur during radiotherapy (RT). The most common and significant side effects (grades 3-5) of cetuximab were acneiform rash (17% vs. 1%, p&amp;lt;0.001) and infusion reaction (3% vs. 0%, p=0.01). Quality of life (QoL) was neither clearly improved nor worsened by the addition of cetuximab to RT. </li>
    <li>Hypomagnesemia was increased in patients receiving cetuximab in combination with cisplatin. </li>
    <li>Gefitinib was associated with an increased incidence of tumour hemorrhage as compared with weekly methotrexate (8.9% for 250mg/d and 11.4% for 500 mg/d vs. 1.9% for methotrexate). </li>
    <li>Concurrent chemotherapy is not only associated with additional adverse effects such as nausea, vomiting, and neutropenia but also with severe oropharyngeal mucositis in over 50% of patients. The latter represents a serious challenge to the quality of life, costs, and management of these patients. </li>
</ul>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Chemoradiotherapy (CRT) is the current standard of care for many patients with locally advanced head and neck squamous cell carcinoma (HNSCC), and, to date, there is not adequate evidence for assessing comparisons of cetuximab plus radiotherapy (RT) to CRT or examining whether the addition of cetuximab to CRT is of benefit to these patients. However, there are six ongoing trials investigating the effect of the addition of epidermal growth factor receptor (EGFR) inhibitors, concurrently with, prior to, or following CRT, on overall survival (OS), progression-free survival (PFS), and time to local recurrence in these patients, which should determine whether cetuximab should be added to standard of care treatment. </li>
    <li>Postoperative CRT is also a standard of care for high-risk patients with HNSCC treated with primary surgery, and no evidence from randomized controlled trials (RCTs) is available to support the use of cetuximab plus RT in this setting. </li>
    <li>Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Quick Reference Guides/Physician Guides"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Safety"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Winquist E, Cripps C, Agbassi C, Messersmith H, Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer. Toronto (ON): Cancer Care Ontario (CCO); 2011 Sep 30. Various p.&amp;nbsp;(Evidence-based series; no. 5-12).&amp;nbsp; [63 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2009 May 15 (revised 2011 Sep 30)"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="123" ordby="1230" id="448" name="Guideline Developer Comment" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.</p></div>"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from the Ontario Ministry of Health and Long-Term Care.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Head and Neck Cancer Disease Site Group</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>For a current list of past and present members, please see the <a href=&quot;http://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/head-neck-ebs/head-neck-dsg/&quot; title=&quot;CCO Web site&quot;>Cancer Care Ontario Web site</a>.</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The authors declared that they have no competing interest.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Cripps C, Winquist E, Stys-Norman D, Devries M, Gilbert R, Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer: guideline recommendations. Toronto (ON): Cancer Care Ontario (CCO); 2009 May 15. 32 p.&amp;nbsp;(Evidence bases series; no. 5-12).</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=44115&quot; title=&quot;CCO Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=44115&quot; title=&quot;CCO Web site&quot;>Cancer Care Ontario Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following are available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer. Summary. Toronto (ON): Cancer Care Ontario (CCO); 2011 Sep 30. 7 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=44117&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario (CCO) Web site</a>. </li>
    <li>Program in Evidence-Based Care (PEBC) handbook. Toronto (ON): Cancer Care Ontario (CCO); 2012. 14 p. Electronic copies: Available in PDF from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=50876&quot; title=&quot;Cancer Care Ontario Web site&quot;>CCO Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on December 30, 2009. This NGC summary was updated by ECRI Institute on September 6, 2013.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the <a href=&quot;http://www.cancercare.on.ca/ontariocancernews/copyright.html&quot; title=&quot;CCO Web site&quot;>Copyright and Disclaimer Statements</a> posted at the Program in Evidence-based Care section of the Cancer Care Ontario Web site.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href=&quot;/about/inclusion-criteria.aspx&quot;>http://www.guideline.gov/about/inclusion-criteria.aspx</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 21:56:32 Sep 30, 2016 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 01:15:25 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 70.455 (3)
  esindex: 0.012
  captures_list: 90.215
  CDXLines.iter: 13.841 (3)
  PetaboxLoader3.datanode: 270.332 (4)
  exclusion.robots: 0.487
  exclusion.robots.policy: 0.461
  RedisCDXSource: 1.904
  PetaboxLoader3.resolve: 121.102
  load_resource: 344.045
-->